Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.05, Briefing.com reports. Enanta Pharmaceuticals had a negative return on equity of 4.94% and a negative net margin of 28.68%. The firm had revenue of $7.51 million during the quarter, compared to analysts’ expectations of $8.08 million. During the same quarter in the previous year, the business earned ($0.06) earnings per share. The company’s revenue was down 46.3% on a year-over-year basis.
Shares of Enanta Pharmaceuticals (ENTA) traded up 4.9626% during mid-day trading on Tuesday, hitting $40.4106. The company had a trading volume of 144,771 shares. The company has a 50-day moving average price of $36.29 and a 200-day moving average price of $32.18. Enanta Pharmaceuticals has a 1-year low of $21.00 and a 1-year high of $41.20. The company’s market capitalization is $771.16 million.
Several hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its stake in shares of Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock valued at $12,723,000 after buying an additional 233,265 shares in the last quarter. State Street Corp raised its stake in shares of Enanta Pharmaceuticals by 31.8% in the first quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock valued at $23,063,000 after buying an additional 180,586 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in shares of Enanta Pharmaceuticals by 50.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 356,000 shares of the biotechnology company’s stock valued at $10,965,000 after buying an additional 120,000 shares in the last quarter. ING Groep NV acquired a new stake in shares of Enanta Pharmaceuticals during the second quarter valued at approximately $3,274,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $1,731,000. Hedge funds and other institutional investors own 65.95% of the company’s stock.
ENTA has been the subject of several recent analyst reports. Zacks Investment Research cut Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 12th. ValuEngine upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. JMP Securities upgraded Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price target for the company in a research note on Tuesday, July 11th. BidaskClub cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, Robert W. Baird boosted their price target on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $33.00.
TRADEMARK VIOLATION NOTICE: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/enanta-pharmaceuticals-inc-nasdaqenta-releases-quarterly-earnings-results-beats-estimates-by-0-05-eps.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.